GHRP-2 Mechanism of Action — Research Reference
Ghrelin receptor agonism, Gαq/PLC and Gαs/cAMP signalling, and the cross-pathway ACTH/prolactin elevation that distinguishes GHRP-2 from ipamorelin.
GHRP-2 Mechanism of Action — Research Reference
GHRP-2 (Pralmorelin; D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide growth hormone secretagogue and one of the most pharmacologically active members of the GHRP class.
Receptor Target
GHRP-2 is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor. Compared to ipamorelin, its binding is less restricted: at GH-effective doses it produces measurable secondary effects on the hypothalamic-pituitary-adrenal axis.
Signal Transduction
Like other GHRPs, GHRP-2 signalling proceeds through:
- Gαq/11 → PLC-β → IP3/DAG → intracellular Ca²⁺ release.
- Gαs → cAMP → PKA — secondary contribution potentiating GHRH signalling.
- Inhibition of somatostatinergic tone at the hypothalamus.
Why Cortisol and Prolactin Rise
GHRP-2 binding extends to corticotrope and lactotrope populations expressing GHS-R1a (or homologous receptors). Published dose-response work consistently shows acute ACTH and prolactin elevation 30–60 minutes after dosing — typically modest at research doses but clearly distinguishable from ipamorelin's clean profile.
Pharmacokinetics
Subcutaneous GHRP-2 produces a rapid GH pulse peaking near 15–30 minutes. Half-life is approximately 15–25 minutes. The D-amino acid scaffold provides resistance to peptidase cleavage.
Synergy with GHRH Analogues
GHRP-2 + a GHRH analogue (CJC-1295, sermorelin) produces the same synergistic GH release described for the ipamorelin/GHRH combination. Researchers favouring GHRP-2 over ipamorelin typically prioritize the larger acute GH-pulse amplitude.
Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.
References
- Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21–31.
- Bowers CY. Editorial: a new dimension on the induced release of growth hormone in obese subjects. J Clin Endocrinol Metab. 1993;76(3):817–818.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.
Related Research Articles
GHRP-6 Mechanism of Action — Research Reference
Ghrelin receptor agonism, central appetite-stimulating signal via NPY/AgRP neurons, and the secondary cortisol/prolactin profile distinguishing GHRP-6 in research.
Hexarelin Mechanism of Action — Research Reference
GHS-R1a and CD36 dual binding, cardioprotective signalling pathways, and the high-potency GH pulse profile that defines hexarelin in research.
CJC-1295 Mechanism of Action — Research Reference
GHRH receptor agonism, Gαs/cAMP/PKA signalling, and the DAC albumin-binding chemistry that converts a 30-minute peptide into a multi-day depot.
Ipamorelin Mechanism of Action — Research Reference
Selective ghrelin/GHS-R1a agonism, Gαq/PLC and Gαs/cAMP signalling, and the receptor selectivity that explains ipamorelin's clean cortisol/prolactin profile.
Sermorelin Mechanism of Action — Research Reference
GHRH receptor binding, Gαs/cAMP signalling, and the short-half-life pulse-preserving profile that makes sermorelin the reference GHRH analogue.
GHK-Cu Mechanism of Action — Research Reference
Copper-coordination chemistry, gene-expression modulation, SOD/antioxidant activity, and matrix remodelling pathways defining GHK-Cu in tissue-repair research.
Related Research Materials
Parent Research Hubs
Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.